The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The Government indemnified AZ, so any compensation will be paid by them not AZ
Thoughts please:
1. Inheritance tax benefits of BPR-qualifying AIM companies
2. Rishi Sunak’s rumoured plans to abolish IHT.
If the need to protect wealth from IHT is removed, what are your thoughts on the prospects for the wider AIM market.
Is License Agreement with Genmab open ended? I have had a look at the RNS but no mention of an end date. Just wondering if there is any incentive for Genmab to get a wriggle on. Other than making money out of marketing a product ASAP of course.
https://www.edisongroup.com/research/sdc-1801-trial-application-refiled-in-australia/32087/
"AZ is also looking for "external opportunities,” Soriot told the news service. The drugmaker is eying bolt-on deals, which could include small and mid-sized companies well-versed in the oncology and cardiovascular arenas, he added."
https://www.fiercepharma.com/pharma/astrazeneca-ceo-cant-be-sure-covid-shot-vaxzevrias-future-company-weighs-wider-split
Good point Blue. But if I am not seriously considering selling, I tend just to have a quick squint at the LSE Bid price to see if it is up or down. You are quite right though, it often bears very little resemblance to what you could actually sell for.
The 10k figure refers to death certificates that just mention Covid alone. But Covid causes so many other conditions like pneumonia, blood clots and many other causes of death which should also be mentioned on the death certificate. Listen to More or Less on the BBC for a full de-bunking. 150k is the far more accurate figure.